title: FDG PET imaging in the evaluation of post-transplant lymphoproliferative disorder following renal transplantation.
abstract: OBJECTIVE
  To assess the usefulness of fluorodeoxyglucose positron emission tomography (FDG PET) in the evaluation of post-transplant lymphoproliferative disorder (PTLD) following renal transplantation.
  
  
  METHODS
  Staging FDG PET examinations were reviewed in five patients with biopsy proven post-renal allograft PTLD and compared with conventional imaging. Follow-up PET examinations of three patients at various points during their therapy for PTLD were also reviewed and compared with clinical outcome.
  
  
  RESULTS
  PET imaging identified all disease sites seen at cross-sectional imaging, clarified sites of uncertain significance and detected additional disease in two out of five patients. Early follow-up imaging impacted PTLD management in two of three patients.
  
  
  CONCLUSIONS
  In this limited series FDG PET was an effective imaging modality in the staging and follow-up of PTLD.
authors.affiliation: Department of Radiology, Nottingham City Hospital, UK.
authors.forename: Angus R
authors.initials: AR
authors.lastname: O'Conner
authors.forename: Benjamin L
authors.initials: BL
authors.lastname: Franc
mesh_terms: D000293:Adolescent; D000328:Adult; D001706:Biopsy; D002648:Child; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000494:pharmacology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D016030:Kidney Transplantation / Q000009:adverse effects*; D008232:Lymphoproliferative Disorders / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology*; D008297:Male; D049268:Positron-Emission Tomography; D011183:Postoperative Complications; D019275:Radiopharmaceuticals / Q000494:pharmacology; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed; D014915:Whole-Body Counting
chemical_list: D007166:Immunosuppressive Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18